Agile Therapeutics, Inc. (AGRX): Price and Financial Metrics
GET POWR RATINGS... FREE!
AGRX Stock Summary
- With a year-over-year growth in debt of -88.63%, AGILE THERAPEUTICS INC's debt growth rate surpasses only 1.59% of about US stocks.
- In terms of volatility of its share price, AGRX is more volatile than 96.8% of stocks we're observing.
- AGILE THERAPEUTICS INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -354.8%, greater than the shareholder yield of just 1.81% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to AGILE THERAPEUTICS INC are CNMD, ASUR, RKDA, IAC, and CMCO.
- AGRX's SEC filings can be seen here. And to visit AGILE THERAPEUTICS INC's official web site, go to www.agiletherapeutics.com.
AGRX Valuation Summary
- AGRX's price/sales ratio is 1; this is 78.72% lower than that of the median Healthcare stock.
- AGRX's price/earnings ratio has moved up 5.5 over the prior 107 months.
Below are key valuation metrics over time for AGRX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| AGRX | 2023-03-17 | 1 | 1.4 | -0.1 | -0.1 |
| AGRX | 2023-03-16 | 1 | 1.4 | -0.1 | -0.1 |
| AGRX | 2023-03-15 | 1 | 1.4 | -0.1 | -0.1 |
| AGRX | 2023-03-14 | 1 | 1.4 | -0.1 | -0.1 |
| AGRX | 2023-03-13 | 1 | 1.4 | -0.1 | -0.1 |
| AGRX | 2023-03-10 | 1 | 1.4 | -0.1 | -0.1 |
AGRX Growth Metrics
- The 3 year cash and equivalents growth rate now stands at -67.62%.
- Its 2 year price growth rate is now at -98.54%.
- Its 5 year net income to common stockholders growth rate is now at 24.6%.
The table below shows AGRX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 8.403 | -51.006 | -67.011 |
| 2022-06-30 | 6.688 | -52.883 | -64.117 |
| 2022-03-31 | 5.747 | -65.285 | -69.535 |
| 2021-12-31 | 4.101 | -65.202 | -74.894 |
| 2021-09-30 | 3.337 | -65.926 | -69.157 |
| 2021-09-30 | 3.337 | -65.926 | -69.157 |
AGRX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- AGRX has a Quality Grade of D, ranking ahead of 15.23% of graded US stocks.
- AGRX's asset turnover comes in at 0.06 -- ranking 307th of 682 Pharmaceutical Products stocks.
- EVFM, ARMP, and EVOK are the stocks whose asset turnover ratios are most correlated with AGRX.
The table below shows AGRX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.060 | -0.588 | -1.478 |
| 2021-06-30 | 0.030 | -0.262 | -1.156 |
| 2021-03-31 | 0.011 | -0.668 | -0.869 |
| 2020-12-31 | 0.008 | 0.623 | -0.805 |
| 2020-09-30 | 0.000 | NA | -0.818 |
| 2020-06-30 | 0.000 | NA | -0.888 |
AGRX Price Target
For more insight on analysts targets of AGRX, see our AGRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $5.00 | Average Broker Recommendation | 1.25 (Strong Buy) |
AGRX Stock Price Chart Interactive Chart >
AGRX Price/Volume Stats
| Current price | $0.27 | 52-week high | $11.40 |
| Prev. close | $0.24 | 52-week low | $0.18 |
| Day low | $0.24 | Volume | 4,955,000 |
| Day high | $0.29 | Avg. volume | 752,762 |
| 50-day MA | $0.26 | Dividend yield | N/A |
| 200-day MA | $0.42 | Market Cap | 10.84M |
Agile Therapeutics, Inc. (AGRX) Company Bio
Agile Therapeutics, Inc. focuses on the development and commercialization of prescription contraceptive products for women. The company was founded in 1997 and is based in Princeton, New Jersey.
Latest AGRX News From Around the Web
Below are the latest news stories about AGILE THERAPEUTICS INC that investors may wish to consider to help them evaluate AGRX as an investment opportunity.
Agile Therapeutics Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price RequirementPRINCETON, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile” or the “Company”), a women's healthcare company, today announced that it has received written notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) granting the Company’s request for a 180-day extension to regain compliance under Nasdaq Listing Rule 5550(a)(2). The Company now has until August 14, 2023 to meet the requirement (the “Compliance Date”). The |
Are Medical Stocks Lagging Ardelyx (ARDX) This Year?Here is how Ardelyx (ARDX) and Agile Therapeutics (AGRX) have performed compared to their sector so far this year. |
Corium Pharma Solutions Names Ernie De Paolantonio as Chief Financial OfficerCorium Pharma Solutions, Inc. (CPSI), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies for prescription drug and consumer products including transdermal modalities, has named Ernie De Paolantonio as Chief Financial Officer. This announcement follows the recent appointments of several industry veterans, Mark Sirgo as Chief Executive Officer, Kevin Ostrander as Chief Business Officer and Dr. Niraj Vasisht as Chief Technolo |
Corium Pharma Solutions Names Two Industry Veterans to its Executive TeamCorium Pharma Solutions, Inc. (CPSI), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies for prescription drug and consumer products including transdermal modalities, has named Kevin Ostrander as Chief Business Officer and Dr. Niraj Vasisht as Chief Technology Officer. These appointments, including CPSI's recent announcement that Mark Sirgo had been named Chief Executive Officer, further strengthen CPSI's executive team an |
Is Ardelyx (ARDX) Stock Outpacing Its Medical Peers This Year?Here is how Ardelyx (ARDX) and Agile Therapeutics (AGRX) have performed compared to their sector so far this year. |
AGRX Price Returns
| 1-mo | 4.05% |
| 3-mo | 38.82% |
| 6-mo | -2.95% |
| 1-year | -97.45% |
| 3-year | -99.57% |
| 5-year | -99.76% |
| YTD | 18.94% |
| 2022 | -98.84% |
| 2021 | -82.99% |
| 2020 | 14.80% |
| 2019 | 331.03% |
| 2018 | -78.44% |
Loading social stream, please wait...